Saturday, 31 October 2026European Markets

VASTNED BELGIUM, TEXAF, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(VIANEWS) - VASTNED BELGIUM (VASTB.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Real Estate sector.

Financial Asset Price Forward Dividend Yield Return on Equity
VASTNED BELGIUM (VASTB.BR) €29.00 7.93% 4.87%
TEXAF (TEXF.BR) €37.40 4.42% 10.64%
CTP (CTPNV.AS) €16.96 3.25% 15.53%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. VASTNED BELGIUM (VASTB.BR)

7.93% Forward Dividend Yield and 4.87% Return On Equity

Vastned Belgium is a public regulated real estate company (RREC), the shares of which are listed on Euronext Brussels (VASTB). Vastned Belgium invests exclusively in Belgian commercial real estate, more specifically in multi-functional retail properties located in the popular shopping cities of Antwerp, Brussels, Ghent and Bruges. The real estate portfolio also comprises high-end retail parks and retail warehouses. A smaller part of the portfolio is invested in hospitality and residential units.

Earnings Per Share

As for profitability, VASTNED BELGIUM has a trailing twelve months EPS of €2.36.

PE Ratio

VASTNED BELGIUM has a trailing twelve months price to earnings ratio of 12.29. Meaning, the purchaser of the share is investing €12.29 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.87%.

Volatility

VASTNED BELGIUM's last week, last month's, and last quarter's current intraday variation average was a positive 0.09%, a negative 0.14%, and a positive 1.08%.

VASTNED BELGIUM's highest amplitude of average volatility was 0.61% (last week), 1.37% (last month), and 1.08% (last quarter).

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on May 6, 2024, the estimated forward annual dividend rate is 2.3 and the estimated forward annual dividend yield is 7.93%.

Moving Average

VASTNED BELGIUM's value is below its 50-day moving average of €29.70 and under its 200-day moving average of €29.06.

More news about VASTNED BELGIUM.

2. TEXAF (TEXF.BR)

4.42% Forward Dividend Yield and 10.64% Return On Equity

Texaf S.A. develops, owns, and leases real estate properties in Kinshasa. It operates through Real Estate, Digital, and Quarries segments. The company's portfolio comprises 332 homes, including 53 villas and 289 apartments with a residential area of 62,200 square meters; 26,300 square meters of office and commercial space; and 30,000 square meters of warehouses, as well as TEXAF digital campus. It also supplies sandstones for use in concrete production, asphalt for roads, and civil engineering projects. Texaf S.A. was founded in 1925 and is headquartered in Brussels, Belgium. Texaf S.A. is a subsidiary of Société Financière Africaine.

Earnings Per Share

As for profitability, TEXAF has a trailing twelve months EPS of €3.18.

PE Ratio

TEXAF has a trailing twelve months price to earnings ratio of 11.76. Meaning, the purchaser of the share is investing €11.76 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.64%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 4.2%, now sitting on 29.07M for the twelve trailing months.

More news about TEXAF.

3. CTP (CTPNV.AS)

3.25% Forward Dividend Yield and 15.53% Return On Equity

CTP N.V., together with its subsidiaries, develops, owns, operates, and leases commercial real estate properties in Central, Western, and Eastern Europe. It offers industrial properties for various applications, such as warehousing, manufacturing, research and development, and bespoke property applications. The company also develops city-center office campuses and parks. In addition, it is involved in the solar energy business. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. CTP N.V. operates as a subsidiary of CTP Holding B.V.

Earnings Per Share

As for profitability, CTP has a trailing twelve months EPS of €2.07.

PE Ratio

CTP has a trailing twelve months price to earnings ratio of 8.19. Meaning, the purchaser of the share is investing €8.19 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.53%.

Volume

Today's last reported volume for CTP is 19431 which is 78.89% below its average volume of 92081.

Yearly Top and Bottom Value

CTP's stock is valued at €16.96 at 02:30 EST, below its 52-week high of €17.02 and way above its 52-week low of €11.50.

More news about CTP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com